866-997-4948(US-Canada Toll Free)

Short Bowel Syndrome Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Published By :

Transparency Market Research

Published Date : Jan 2017

Category :

Pharmaceutical

No. of Pages : 124 Pages

Global Short Bowel Syndrome Market: Overview

Short bowel syndrome (SBS) is an intestinal disorder associated with malabsorption due to the lack of functional intestine. SBS can be congenital or an acquired condition which can be observed in patients in whom nearly half of the small intestine has been removed due to underlying disease condition. In certain instances, a major part of the large intestine is removed through surgeries that might result in SBS in the patients. The major causes of SBS in infants include necrotizing enterocolitis, intestinal atresia, gastroschisis, and malrotation with volvulus, among others. In adults, SBS is observed in Crohn’s disease, radiation enteritis, and mesenteric ischemia, among others. The medications prescribed for the treatment of SBS include teduglutide and growth hormones (aid in intestinal absorption), proton pump inhibitors (used to treat gastric acid secretions), and anti-diarrheal (to treat the primary symptom of SBS, i.e., diarrhea). As the patients with SBS have lost major part of the intestine, retaining nutrients in such patients through oral nutrition becomes difficult. Hence parenteral nutrition is the preferred mode of treatment in these patients. 

Global Short Bowel Syndrome Market: Research Methodologies

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of drugs employed in the treatment of short bowel syndrome in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for drug class, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each drug class was calculated by considering prevalence rate of short bowel syndrome, the cost of the drugs, reimbursement scenario, drug availability, patent expiries, and adoption rate of the drugs, across all the geographies.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on drug class, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the short bowel syndrome market in the current and future scenario. The report also provides value chain analysis of the market that describes the sequence of activities involved, from identification of the market need to their final reach to the end users.

Global Short Bowel Syndrome Market: Scope of the Study

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, and Rest of the World. The study also covers detailed country analysis contributing majorly in the short bowel syndrome market.

Key Players Mentioned in this Report are:

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Companies profiled in the short bowel syndrome market report are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, and Zealand Pharma A/S, among others.

The Short Bowel Syndrome Market has been segmented as follows:

Short Bowel Syndrome Market, by Drug Class, Revenue (US$ Mn) 2014-2024

  • GLP-2
  • Growth Hormone
  • Glutamine
  • Others

Short Bowel Syndrome Market Revenue, by Geography (US$ Mn), 2014-2024

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
  • Rest of the World

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Short Bowel Syndrome

4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global Short Bowel Syndrome Analysis and Forecasts, 2014–2024
4.3.3. Market Revenue Projections (US$ Mn)
4.4. Porter’s Five Force Analysis
4.5. Value Chain Analysis
4.6. Market Outlook
4.7. Disease Overview
4.8. Disease Epidemiology
4.9. Patent Information
4.10. Overview of Clinical Trials
4.11. Qualitative Analysis of GLP-2 product
4.12. Mode of action of SBS drugs
4.13. Regulatory Scenario

5. Global Short Bowel Syndrome Analysis and Forecasts, By Drug Class 
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
5.4.1. GLP-2 
5.4.2. Growth Hormone
5.4.3. Glutamine
5.4.4. Others
5.5. Market Attractiveness by Drug Class 

6. Global Short Bowel Syndrome Analysis and Forecasts, By Region
6.1. Key Findings
6.2. Market Value (US$ Mn) Forecast By Region
6.2.1. North America
6.2.2. Europe 
6.2.3. Rest of the World 
6.3. Market Attractiveness by Country/Region

7. North America Short Bowel Syndrome Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.1.2. Key Trends
7.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
7.2.1. GLP-2 
7.2.2. Growth Hormone
7.2.3. Glutamine
7.2.4. Others
7.3. Market Value (US$ Mn) Forecast By Country, 2014–2024
7.3.1. U.S. 
7.3.2. Canada
7.3. Market Attractiveness Analysis 
7.3.1. By Drug Class 
7.3.2. By Country

8. Europe Short Bowel Syndrome Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Key Trends
8.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
8.2.1. GLP-2 
8.2.2. Growth Hormone
8.2.3. Glutamine
8.2.4. Others
8.3. Market Value (US$ Mn) Forecast By Country, 2014–2024
8.3.1. U.K.
8.3.2. Germany
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Market Attractiveness Analysis 
8.4.1. By Drug Class 
8.4.2. By Country

9. Rest of the World Short Bowel Syndrome Analysis and Forecast
9.1. Introduction
9.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
9.3. Regional Insights
9.3.1. Japan
9.3.2. India
9.3.3. Australia/New Zealand
9.3.4. China
9.3.5. Middle East
9.3.6. Brazil

10. Competition Landscape
10.1. Market Player – Competition Matrix (By Tier and Size of companies)
10.2. Market Share Analysis by Company (2015)
10.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
10.3.1. Ardelyx, Inc.
10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.1.2. Business Overview
10.3.1.3. Product Portfolio 
10.3.1.4. Financial Overview 
10.3.1.5. SWOT Analysis 
10.3.1.6. Strategic overview
10.3.2. Emmaus Life Sciences, Inc.
10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.2.2. Business Overview
10.3.2.3. Product Portfolio 
10.3.2.4. Financial Overview 
10.3.2.5. SWOT Analysis 
10.3.2.6. Strategic overview
10.3.3. GLyPharma Therapeutic, Inc.
10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.3.2. Business Overview
10.3.3.3. Product Portfolio 
10.3.3.4. Financial Overview 
10.3.3.5. SWOT Analysis 
10.3.3.6. Strategic overview
10.3.4. Merck KGaA
10.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.4.2. Business Overview
10.3.4.3. Product Portfolio 
10.3.4.4. Financial Overview 
10.3.4.5. SWOT Analysis 
10.3.4.6. Strategic overview
10.3.5. Naia Pharmaceuticals, Inc.
10.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.5.2. Business Overview
10.3.5.3. Product Portfolio 
10.3.5.4. Financial Overview 
10.3.5.5. SWOT Analysis 
10.3.5.6. Strategic overview
10.3.6. Nutrinia Ltd.
10.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.6.2. Business Overview
10.3.6.3. Product Portfolio 
10.3.6.4. Financial Overview 
10.3.6.5. SWOT Analysis 
10.3.6.6. Strategic overview
10.3.7. OxThera
10.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.7.2. Business Overview
10.3.7.3. Product Portfolio 
10.3.7.4. Financial Overview 
10.3.7.5. SWOT Analysis 
10.3.7.6. Strategic overview
10.3.8. Sancilio & Company, Inc.
10.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.8.2. Business Overview
10.3.8.3. Product Portfolio 
10.3.8.4. Financial Overview 
10.3.8.5. SWOT Analysis 
10.3.8.6. Strategic overview
10.3.9. Shire plc
10.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.9.2. Business Overview
10.3.9.3. Product Portfolio 
10.3.9.4. Financial Overview 
10.3.9.5. SWOT Analysis 
10.3.9.6. Strategic overview
10.3.10. Zealand Pharma A/S
10.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.10.2. Business Overview
10.3.10.3. Product Portfolio 
10.3.10.4. Financial Overview 
10.3.10.5. SWOT Analysis 
10.3.10.6. Strategic overview

List of Table

Table 01: Overview of clinical trials for short bowel syndrome
Table 02: Global Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 03: Global Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 04: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 05: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 06: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 07: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Country, 2014–2024    

List of Chart

Figure 01: Global Short Bowel Syndrome Size (US$ Mn) and Forecast, 2016–2024
Figure 02: Global Market Value Share, by Drug Class (2016)
Figure 03: Global Market Value Share, by Region (2016)
Figure 04: Causes of SBS in neonates in neonatal intensive care units (NICU)
Figure 05: Causes of SBS in adults
Figure 06: Global Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and
Figure 07: Global GLP-2 Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 08: Global Growth Hormone Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Global Glutamine Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class
Figure 12: Global Short Bowel Syndrome Market Revenue, US$ Mn, 2014–2024
Figure 13: Global Short Bowel Syndrome Market Value Share Analysis, by Region, 2015 and 2024
Figure 14: Short Bowel Syndrome Market Attractiveness Analysis, by Region
Figure 15: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 16: North America Market Attractiveness Analysis, by Drug Class
Figure 17: North America Market Attractiveness Analysis, by Country
Figure 18: North America Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 19: North America Short Bowel Syndrome Market Value Share Analysis, by Country, 2015 and 2024 
Figure 20: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 21: Europe Market Attractiveness Analysis, by Drug Class
Figure 22: Europe Market Attractiveness Analysis, by Country
Figure 23: Europe Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 24: Europe Short Bowel Syndrome Market Value Share Analysis, by Country, 2015 and 2024
Figure 25: Rest of the World Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 26: Global Short Bowel Syndrome Market Share Analysis, by Company (2015)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *